Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

EpiPen Price Story Highlights Growing Impact Of Drug Deductibles

Executive Summary

Nearly half of employer-sponsored insurance plans surveyed require members to meet a deductible before coverage for a prescription drug is approved.

Advertisement

Related Content

EpiPen Competitor Auvi-Q Relauching With Ultimate Copay: $0
Price Rebates Will Continue As ‘Fact Of Life’ In Drug Contracting
Mylan CEO Takes Center Stage To Address EpiPen Pricing Scandal
US Brand Drug Price Inflation Slowing As Elections Approach
Drug Cost Blame Game: Payers’ Contribution To Prices Getting More Attention
Mylan's Generic EpiPen: A Good PR Move, But Risks Alienating Payers
EpiPen's Swollen Price May Trigger Patient Assistance Program Probes

Topics

Advertisement
UsernamePublicRestriction

Register

PS119033

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel